Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type
S Unizony, M Villarreal, EM Miloslavsky, N Lu… - Annals of the rheumatic …, 2016 - Elsevier
Objective To evaluate whether the classification of patients with anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3
(PR3) or anti-myeloperoxidase (MPO) antibodies) predicts treatment response. Methods
Treatment responses were assessed among patients enrolled in the Rituximab in ANCA-
associated Vasculitis trial according to both AAV diagnosis (granulomatosis with polyangiitis
(GPA)/microscopic polyangiitis (MPA)) and ANCA type (PR3-AAV/MPO-AAV). Complete …
antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3
(PR3) or anti-myeloperoxidase (MPO) antibodies) predicts treatment response. Methods
Treatment responses were assessed among patients enrolled in the Rituximab in ANCA-
associated Vasculitis trial according to both AAV diagnosis (granulomatosis with polyangiitis
(GPA)/microscopic polyangiitis (MPA)) and ANCA type (PR3-AAV/MPO-AAV). Complete …
